

Monterrey, Mexico. October 16, 2017 - Alpek, S.A.B. de C.V. (BMV: ALPEK)

# Alpek reports 3Q17 EBITDA of U.S. \$3 million, including a U.S. -\$113 million provision covering the full amount of M&G accounts receivable

#### **Selected Financial Information**

(U.S. \$ Millions)

	(%) 3Q17 vs.									
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%		
Total Volume (ktons)	1,012	1,038	998	(2)	1	3,036	2,967	2		
Polyester	788	807	757	(2)	4	2,353	2,254	4		
Plastics & Chemicals	225	231	241	(3)	(7)	683	713	(4)		
Consolidated Revenues	1,312	1,306	1,236	-	6	3,910	3,655	7		
Polyester	945	930	885	2	7	2,791	2,593	8		
Plastics & Chemicals	367	375	351	(2)	4	1,119	1,062	5		
Consolidated EBITDA	3	82	157	(96)	(98)	243	536	(55)		
Polyester	(51)	33	83	(254)	(161)	70	267	(74)		
Plastics & Chemicals	54	49	73	10	(26)	173	270	(36)		
Profit Attributable to Controlling Interest	(400)	25	50	(1,719)	(903)	(289)	170	(270)		
CAPEX and Acquisitions	64	65	128	(2)	(50)	206	270	(24)		
Net Debt	1,192	1,058	915	13	30					
Net Debt/LTM EBITDA <sup>(1)</sup>	3.2	2.0	1.3							
Interest Coverage <sup>(1)</sup>	5.4	8.0	10.8							
(4) T: 1 1 40 11										

<sup>(1)</sup> Times: Last 12 months

## **Operating & Financial Highlights (3Q17)**

Alpek	<ul> <li>One-time charges associated to Mossi &amp; Ghisolfi (M&amp;G): U.S\$113 million A/R provision (EBITDA), U.S\$435 million intangible asset impairment (Oper. Income), U.S\$95 million financial asset impairment (Financial Cost, Net) and U.S. +\$223 million deferred tax</li> <li>3.2 times Net Debt/LTM EBITDA; 2.4 times excluding M&amp;G A/R provision (U.S\$113 million)</li> <li>Offers for power cogeneration assets in final selection stage</li> </ul>
Polyester	<ul> <li>3Q17 Polyester EBITDA of U.S.\$ -51 million, including the U.S\$113 million M&amp;G A/R provision and a U.S. \$9 million non-cash inventory gain</li> <li>PTA supply to M&amp;G was suspended in Mexico (Sep) and Brazil (Aug) due to missed payments</li> <li>Alpek engaging M&amp;G and its key creditors to resume PTA supply</li> </ul>
Plastics & Chemicals (P&C)	<ul> <li>3Q17 P&amp;C EBITDA of U.S. \$54 million; null inventory loss/gain</li> <li>Volume impacted by temporary feedstock supply disruptions, mainly due to Hurricane Harvey</li> <li>Resilient margins in polypropylene (PP), expandable polystyrene (EPS) and caprolactam (CPL)</li> </ul>

This release contains forward-looking information based on numerous variables and assumptions that are inherently uncertain. They involve judgments with respect to, among other things, future economic, competitive and financial market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Accordingly, results could vary from those set forth in this release. The report presents unaudited financial information based on International Financial Reporting Standards (IFRS). Figures are stated in nominal Mexican pesos (\$) and in current U.S. Dollars (U.S. \$), as indicated. Where applicable, peso amounts were translated into U.S. Dollars using the average exchange rate of the months during which operations were recorded. Financial ratios are calculated in U.S. Dollars. Due to the rounding up of figures, small differences may occur when calculating percent changes from one period to the other.



#### Message from the CEO

Alpek's third quarter 2017 financial results include full provisions and asset impairments associated to Mossi & Ghisolfi (M&G) which proceeded to shut down its operations in Altamira, Mx due to liquidity constraints. Missed payments forced Alpek to halt PTA supply to M&G Mexico and M&G Brazil during 3Q17. Since then, Alpek and its advisors have engaged M&G and its creditors to resume PTA supply; a suitable mechanism may be implemented soon.

Exposure to M&G is twofold as of 3Q17: i) PTA accounts receivable (A/R) and ii) funding for its integrated PTA-PET site under construction in Corpus Christi, TX. In accordance with IFRS, Alpek recognized the following non-recurring items: i) U.S. -\$113 million provision for A/R impairment affecting EBITDA, ii) U.S. -\$435 million intangible asset impairment affecting Operating Income or EBIT, iii) U.S. -\$95 million financial asset impairment affecting Financial Cost, Net, and iv) U.S. +\$223 million deferred tax benefiting Income Tax.

The full amount of provisions and asset impairments is subject to restitution upon A/R collection or a definitive Corpus Christi project resolution reaffirming Alpek's capacity rights. Alpek will continue pursuing full restitution by leveraging its competitive PTA supply in Mexico and Brazil as well as its secured claim in Corpus Christi.

In addition to its A/R claim as an M&G Mexico supplier, Alpek acquired from Inbursa all credit rights to a U.S. \$100 million secured loan with M&G Polímeros México S.A. de C.V. (M&G Mexico) earlier this month. Alpek paid a lump sum of U.S. \$101 million for the loan's principal and accrued interest. The acquired credit rights are secured by a first lien on M&G Mexico's PET production facility in Altamira, Mexico which has an installed capacity of approximately 560 Kton per year and is located next to Alpek's largest PTA site. Alpek will continue engaging M&G and its creditors to resume M&G Mexico's operations and implement a restructuring plan for M&G Mexico.

Alpek's Consolidated 3Q17 EBITDA was U.S. \$3 million. Adjusting for the U.S. -\$113 million M&G A/R provision and a U.S. \$9 million inventory gain, Comparable 3Q17 Consolidated EBITDA was U.S. \$108 million, 9% higher than 2Q17 driven mainly by sequential improvement in the Polyester segment.

Polyester EBITDA was U.S. -\$51 million in 3Q17. Adjusting for the M&G A/R provision and inventory gains, Comparable 3Q17 Polyester EBITDA was U.S. \$54 million, up 20% when compared with 2Q17 despite lower PTA sales to M&G. Stable plant operations following multiple unplanned outages in 2Q17 as well as the recent recovery in oil and feedstock prices contributed to sequential Polyester EBITDA growth.

Relevant polyester industry events in 3Q17 include petitions from domestic polyester producers to investigate unfairly traded PET resin imports into the United States and Canada. In the U.S., petitions were filed with the United States Department of Commerce (USDOC) and the United States International Trade Commission (USITC) against five countries: Brazil, Indonesia, Korea, Pakistan and Taiwan. Separately, the Canada Border Services Agency (CBSA) launched an investigation into PET resin imports from China, India, Oman and Pakistan. Before year-end, the USDOC will determine whether to initiate an investigation, the USITC will reach a preliminary determination on whether there is material injury, and the CBSA could apply preliminary import duties.

Plastics & Chemicals (P&C) segment EBITDA posted its third consecutive quarter above Alpek's 2017 Guidance. 3Q17 P&C EBITDA and Comparable P&C EBITDA were U.S. \$54 million as lower volume was more than offset by robust margins. P&C volume was down 3% quarter-on-quarter due to temporary feedstock supply disruptions; most of which were associated to Hurricane Harvey.



Capex totaled U.S. \$64 million in 3Q17 as progress is ongoing in the development of strategic projects such as the 350 MW Altamira power cogeneration plant. An important milestone this quarter was the completion of the Expandable Polystyrene (EPS) capacity expansion project in Altamira, Mexico. Alpek invested a total of U.S. \$33 million to expand its EPS plant by 75 Kton per year to reach 240 Kton per year, making it one of the top five in the world. The additional production unit started its gradual ramp up process in September 2017, a few months ahead of schedule.

The acquisition of PetroquimicaSuape and Citepe from Petrobras for U.S. \$385 million is being evaluated by the Administrative Council for Economic Defense (CADE) in Brazil. Recently, CADE declared this case as "complex" which is a procedural act that allows a 90-day extension to the initial 240-day term for its analysis. Alpek will continue working closely with CADE and Petrobras to obtain approval of the transaction. Closing is subject to CADE's approval, among other conditions.

Another initiative that continued moving forward is the sale of power cogeneration assets in Mexico. Alpek is engaged in the final selection stage to choose one of the offers received from potential investors for its power cogeneration facilities.

Alpek maintains a solid financial position supported by a strong balance sheet and liquidity. At the close of 3Q17, Net Debt totaled U.S. \$1.192 billion and Net Debt to LTM EBITDA was 3.2 times or 2.4 times when adjusted for the U.S. -\$113 million M&G A/R provision that affected EBITDA. Furthermore, the balance of Cash and Cash Equivalents was U.S. \$447 million as of 3Q17.

The recent events associated to M&G's financial situation were not considered in Alpek's 2017 Guidance. Volume, Revenues and EBITDA were negatively impacted in 3Q17 by the current M&G shutdown. However, the total impact in 2017 may vary depending on a number of variables such as the duration of the M&G shutdown or potential impairment restitution, among others. Alpek has limited visibility at this time to provide a reliable 4Q17 outlook.

Looking ahead, the base scenario is for Alpek to resume PTA supply to M&G in the short term. However, even in an extreme full M&G shutdown scenario for 2018, Alpek expects its EBITDA to recover within a range of at least U.S. \$450 to \$500 million based on preliminary estimations. Lost PTA sales to M&G would be partially offset with higher internal PTA consumption, higher domestic PET sales, savings from strategic projects and higher PTA exports. Additionally, 2018 EBITDA would not be affected by the non-recurring M&G A/R provision recognized in 2017.



#### **Results by Business Segment**

#### **Polyester**

(Purified Terephthalic Acid (PTA), Polyethylene Terephthalate (PET), Polyester fibers – 72% of Alpek's Net Sales)

Third quarter 2017 Polyester revenue was up 7% year-on-year and 2% quarter-on-quarter as mixed volume growth was more than offset by higher average prices. Average 3Q17 Polyester prices increased 3% when compared with 3Q16 and 4% versus 2Q17, reflecting the oil and feedstock price recovery observed after 2Q17 as well as a shift in Polyester sales mix caused by lower PTA sales to M&G.

3Q17 Polyester volume increased 4% when compared with 3Q16 but decreased 2% versus 2Q17. The sudden halt of PTA supply to M&G negatively impacted Polyester volume. Year-to-date, Polyester volume is 4% higher than 2016 driven mainly by growth associated to the integration of Selenis Canada Inc. (PET).

Third quarter 2017 segment EBITDA was U.S. -\$51 million, including the U.S. -\$113 million M&G A/R provision and a U.S. \$9 million non-cash inventory gain. Adjusting for the impairment and inventory gain, Comparable 3Q17 Polyester EBITDA was U.S. \$54 million, 36% lower than 3Q16 but up 20% when compared with 2Q17. Comparable Polyester EBITDA posted solid growth quarter-on-quarter driven mainly by the recent recovery in feedstock prices (e.g. paraxylene and monoethylene glycol) as well as restored plant operations after multiple unplanned outages in 2Q17. Lower PTA sales to M&G and incremental secondary feedstock (i.e. isophthalic acid - IPA) costs that have not been fully transferred to PET prices weighed on sequential Comparable Polyester EBITDA growth.

#### Plastics & Chemicals (P&C)

(Polypropylene (PP), Expandable Polystyrene (EPS), Caprolactam (CPL), Other products – 28% of Alpek's Net Sales)

3Q17 P&C revenue increased 4% year-on-year but decreased 2% quarter-on-quarter as lower volume was partially offset by higher average prices. Average third quarter 2017 P&C prices were up 12% and 1% when compared with 3Q16 and 2Q17 respectively, driven mainly by higher feedstock prices.

Third quarter 2017 P&C volume was down 7% and 3% when compared with 3Q16 and 2Q17, respectively. P&C volume was negatively impacted by feedstock supply disruptions in Mexico and the United States. In the case of Mexico, unplanned refinery outages weighed on domestic propylene supply and Alpek's specialty chemical business was subject to lower ethylene oxide supply. Moreover, temporary disruptions associated to Hurricane Harvey affected the supply of certain feedstocks that are imported from the U.S. Gulf Coast.

3Q17 P&C EBITDA and Comparable P&C EBITDA were U.S. \$54 million as lower volume was more than offset by better-than-expected margins. PP margins have been resilient to high feedstock price volatility, while EPS and CPL margins posted sequential improvement after 2Q17. Year-to-date, P&C EBITDA has consistently been above guidance.



#### **Consolidated Financial Results**

**Net Sales:** Net Sales for the third quarter totaled U.S. \$1.3 billion, up 6% year-on-year and flat quarter-on-quarter, mainly due to higher average consolidated prices in both business segments. Average 3Q17 consolidated prices increased 5% and 3% when compared with 3Q16 and 2Q17, respectively. 3Q17 consolidated volume was up 1% year-on-year and down 2% on a quarterly basis. Accumulated net sales as of September 30, 2017 totaled U.S. \$3.9 billion, 7% higher than the same period last year as a result of 5% and 2% increases in average prices and volume respectively.

**EBITDA:** 3Q17 EBITDA was U.S. \$3 million, down 98% and 96% when compared with 3Q16 and 2Q17 respectively. This quarter 2017 Consolidated EBITDA includes a U.S. -\$113 million provision for A/R impairment associated to M&G and a U.S. \$9 million non-cash inventory gain. Adjusting for the M&G A/R impairment and the inventory gain, Comparable Consolidated EBITDA was U.S. \$108 million, U.S. \$99 million and U.S. \$152 million in 3Q17, 2Q17 and 3Q16 respectively. Comparable 3Q17 Consolidated EBITDA decreased 29% year-on-year but increased 9% versus 2Q17 supported by the recent recovery in oil and feedstock prices, better-than-expected P&C margins and improved polyester plant operations following multiple unplanned outages in 2Q17. Accumulated EBITDA as of September 30, 2017 was U.S. \$243 million and accumulated Comparable Consolidated EBITDA totaled U.S. \$338 million.

**Profit (Loss) Attributable to Controlling Interest:** Loss Attributable to Controlling Interest for the third quarter of 2017 was U.S. -\$400 million, compared to U.S. \$50 million and U.S. \$25 million Profit in 3Q16 and 2Q17 respectively. 3Q17 Loss Attributable to Controlling Interest includes an aggregate net impact of U.S. -\$416 million from non-recurring charges associated to M&G affecting EBITDA, Operating Income, Financial Cost, Net and Income Tax. Adjusting for the non-recurring M&G items, the Profit Attributable to Controlling Interest was U.S. \$16 million for the quarter and U.S. \$127 million year-to-date.

Capital Expenditures and Acquisitions (Capex): 3Q17 Capex was U.S. \$64 million, compared to U.S. \$128 million and U.S. \$65 million in 3Q16 and 2Q17 respectively. Year-to-date Capex of U.S. \$206 million is 24% lower than the same period last year as investment ramps down due to completion of strategic projects. The majority of these funds were invested in the 350 MW power cogeneration plant in Altamira, Mexico, which is advancing as planned together with other projects. An important milestone this quarter was the completion of the Expandable Polystyrene (EPS) capacity expansion project in Altamira, Mexico. Alpek invested a total of U.S. \$33 million to expand its EPS plant by 75 Kton per year to reach 240 Kton per year. The additional production unit started its gradual ramp up process in September 2017, a few months ahead of schedule.

**Net Debt:** Consolidated Net Debt as of September 30, 2017 was U.S. \$1.192 billion, up 30% and 13% year-on-year and quarter-on-quarter, respectively. On an absolute basis, Net Debt increased U.S. \$135 million in 3Q17. Dividends and CAPEX were the two largest cash flow line items this quarter. Dividends include U.S. \$72 million paid to shareholders in September, as approved at Alpek's Annual Shareholders Meeting. As of September 30, 2017, Gross Debt was U.S. \$1.639 billion and the Cash balance totaled U.S. \$447 million. Financial ratios at the close of 3Q17 were: Net Debt to LTM EBITDA of 3.2 times and Interest Coverage of 5.4 times. Adjusting for the U.S. -\$113 million M&G A/R provision, Net Debt to LTM EBITDA was 2.4 times and Interest Coverage was 7.0 times.



#### **Appendix A - Tables**

# TABLE 1 | VOLUME (KTONS)

	(%) 3Q17 vs.											
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%				
Total Volume	1,012	1,038	998	(2)	1	3,036	2,967	2				
Polyester	788	807	757	(2)	4	2,353	2,254	4				
Plastics and Chemicals	225	231	241	(3)	(7)	683	713	(4)				

# TABLE 2 | PRICE CHANGES (%)

	(%) 30	17 vs.	YTD17 vs.		
_	2Q17	3Q16	YTD16		
Polyester					
Avg. Ps. Prices	-	(2)	7		
Avg. U.S. \$ Prices	4	3	3		
Plastics and Chemicals					
Avg. Ps. Prices	(3)	7	14		
Avg. U.S. \$ Prices	1	12	10		
Total					
Avg. Ps. Prices	(1)	-	8		
Avg. U.S. \$ Prices	3	5	5		

## TABLE 3 | INCOME STATEMENT (U.S. \$ Millions)

				(%) 30	17 vs.			
	3Q17	2Q17	<b>3Q16</b>	2Q17	3Q16	YTD17	YTD16	Ch.%
Total Revenues	1,312	1,306	1,236	-	6	3,910	3,655	7
Gross Profit	126	85	164	48	(24)	382	573	(33)
Operating expenses and others	(596)	(36)	(42)	(1,560)	(1,310)	(680)	(138)	(393)
Operating income	(470)	49	122	(1,062)	(485)	(298)	435	(169)
Financial cost, net	(130)	(6)	(28)	(2,013)	(367)	(119)	(98)	(22)
Share of losses of associates	-	-	-	142	630	-	-	28
Income Tax	206	(5)	(30)	4,484	795	168	(97)	272
Consolidated net income	(394)	38	65	(1,140)	(709)	(251)	240	(205)
Controlling Interest	(400)	25	50	(1,719)	(903)	(289)	170	(270)





## TABLE 4 | REVENUES

	(%) 3Q17 vs.							
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Total Revenues							-	
Ps. Millions	23,374	24,275	23,132	(4)	1	73,988	66,764	11
U.S. \$ Millions	1,312	1,306	1,236	-	6	3,910	3,655	7
Domestic Revenues								
Ps. Millions	8,060	9,098	8,407	(11)	(4)	26,791	25,134	7
U.S. \$ Millions	452	489	449	(8)	1	1,414	1,377	3
Foreign Revenues								
Ps. Millions	15,314	15,176	14,724	1	4	47,198	41,630	13
U.S. \$ Millions	859	816	787	5	9	2,495	2,278	10
Foreign / Total (%)	66	63	64			64	62	

#### TABLE 5 OPERATING INCOME AND EBITDA

				(%) 3Q	17 vs.			
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Operating Income								
Ps. Millions	(8,377)	904	2,292	(1,027)	(465)	(4,938)	7,919	(162)
U.S. \$ Millions	(470)	49	122	(1,062)	(485)	(298)	435	(169)
EBITDA								
Ps. Millions	59	1,524	2,938	(96)	(98)	4,824	9,778	(51)
U.S. \$ Millions	3	82	157	(96)	(98)	243	536	(55)

## TABLE 6 | COMPARABLE EBITDA

			(%) 3Q:	17 vs.			
3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
59	1,524	2,938	(96)	(98)	4,824	9,778	(51)
3	82	157	(96)	(98)	243	536	(55)
1,863	318	(89)	486	2,201	1,631	(296)	651
105	17	(4)	522	2,437	95	(16)	698
1,922	1,841	2,849	4	(33)	6,454	9,482	(32)
108	99	152	9	(29)	338	520	(35)
	59 3 1,863 105	1,863 318 105 17 1,922 1,841	59     1,524     2,938       3     82     157       1,863     318     (89)       105     17     (4)       1,922     1,841     2,849	3Q17     2Q17     3Q16     2Q17       59     1,524     2,938     (96)       3     82     157     (96)       1,863     318     (89)     486       105     17     (4)     522       1,922     1,841     2,849     4	59     1,524     2,938     (96)     (98)       3     82     157     (96)     (98)       1,863     318     (89)     486     2,201       105     17     (4)     522     2,437       1,922     1,841     2,849     4     (33)	3Q17         2Q17         3Q16         2Q17         3Q16         YTD17           59         1,524         2,938         (96)         (98)         4,824           3         82         157         (96)         (98)         243           1,863         318         (89)         486         2,201         1,631           105         17         (4)         522         2,437         95           1,922         1,841         2,849         4         (33)         6,454	3Q17         2Q17         3Q16         2Q17         3Q16         YTD17         YTD16           59         1,524         2,938         (96)         (98)         4,824         9,778           3         82         157         (96)         (98)         243         536           1,863         318         (89)         486         2,201         1,631         (296)           105         17         (4)         522         2,437         95         (16)           1,922         1,841         2,849         4         (33)         6,454         9,482





#### TABLE 7 | FINANCIAL COST, NET (U.S. \$ Millions)

				(%) 3Q17 vs.				
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Financial Expenses	(19)	(19)	(19)	(1)	3	(55)	(59)	7
Financial Income	2	3	3	(46)	(39)	8	11	(23)
Net Financial Expenses	(17)	(15)	(16)	(10)	(3)	(46)	(48)	4
Financial Assets Impairment	(95)	-	-	(100)	(100)	(95)	-	(100)
Fx Gains (Losses)	(18)	9	(11)	(290)	(57)	22	(49)	145
Financial Cost, Net	(130)	(6)	(28)	(2,013)	(367)	(119)	(98)	(22)

#### TABLE 8 | NET INCOME (U.S. \$ Millions)

		(%)3Q17 vs.						
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Consolidated Net Income	(394)	38	65	(1,140)	(709)	(251)	240	(205)
Non-Controlling Interest	6	13	15	(53)	(58)	38	70	(45)
Controlling Interest	(400)	25	50	(1,719)	(903)	(289)	170	(270)
Earnings per Share (U.S. Dollars)	(0.19)	0.01	0.02	(1,719)	(903)	(0.14)	0.08	(270)
Avg. Outstanding Shares (Millions)*	2,117	2,117	2,118			2,117	2,118	

<sup>\*</sup> The same number of equivalent shares are considered in the periods presented

#### TABLE 9 | CASH FLOW (U.S. \$ Millions)

				(%) 3Q	17 vs.			
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
EBITDA	3	82	157	(96)	(98)	243	536	(55)
Net Working Capital & Others	29	156	37	(81)	(21)	121	(100)	221
Capital Expenditures & Acq.	(64)	(65)	(128)	2	50	(206)	(270)	24
Financial Expenses	(17)	(17)	(18)	(5)	5	(50)	(41)	(21)
Income tax	(19)	(33)	(23)	43	18	(78)	(142)	45
Dividends	(71)	(9)	-	(712)	(100)	(168)	(205)	18
Payment affiliated companies	-	1	(4)	(100)	100	1	60	(99)
Other Sources / Uses	5	3	(25)	76	119	(13)	(32)	60
Decrease (Increase) in Net Debt	(135)	118	(4)	(214)	(2,947)	(151)	(193)	22



## TABLE 10 | STATEMENT OF FINANCIAL POSITION & FINANCIAL RATIOS (U.S. \$ Millions)

				(%) 3Q:	17 vs.
_	3Q17	2Q17	3Q16	2Q17	3Q16
Assets	-	-			
Cash and cash equivalents	447	188	240	138	86
Trade accounts receivable	507	577	555	(12)	(9)
Inventories	726	732	694	(1)	5
Other current assets	296	276	308	7	(4)
Total current assets	1,975	1,773	1,796	11	10
Investment in associates and others	33	29	44	11	(26)
Property, plant and equipment, net	2,117	2,088	1,872	1	13
Goodwill and intangible assets, net	211	574	590	(63)	(64)
Other non-current assets	227	234	128	(3)	77
Total assets	4,563	4,698	4,430	(3)	3
Liabilities & stockholders' equity					
Debt	380	236	97	61	291
Suppliers	741	763	624	(3)	19
Other current liabilities	186	186	206	-	(10)
Total current liabilities	1,307	1,184	927	10	41
Debt	1,254	1,004	1,051	25	19
Employees' benefits	61	61	67	1	(8)
Other long term liabilities	312	371	354	(16)	(12)
Total liabilities	2,935	2,620	2,400	12	22
Total stockholders' equity	1,628	2,079	2,031	(22)	(20)
Total liabilities & stockholders' equity	4,563	4,698	4,430	(3)	3
Net Debt	1,192	1,058	915	13	30
Net Debt/EBITDA*	3.2	2.0	1.3		
Interest Coverage*	5.4	8.0	10.8		

<sup>\*</sup> Times: last 12 months



# **Polyester**

## TABLE 11 | REVENUES

				(%) 3Q17 vs.				
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Total Revenues								
Ps. Millions	16,836	17,303	16,559	(3)	2	52,808	47,378	11
U.S. \$ Millions	945	930	885	2	7	2,791	2,593	8
Domestic Revenues								
Ps. Millions	4,108	4,652	4,418	(12)	(7)	13,766	12,618	9
U.S. \$ Millions	230	250	236	(8)	(2)	726	691	5
Foreign Revenues								
Ps. Millions	12,727	12,651	12,141	1	5	39,042	34,760	12
U.S. \$ Millions	714	680	649	5	10	2,065	1,902	9
Foreign / Total (%)	76	73	73			74	73	

# TABLE 12 | OPERATING INCOME AND EBITDA

				(%) 3Q17 vs.				
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Operating Income								
Ps. Millions	(9,208)	118	1,052	(7,919)	(976)	(7,837)	3,409	(330)
U.S. \$ Millions	(517)	7	56	(8,032)	(1,024)	(450)	187	(341)
EBITDA								
Ps. Millions	(899)	607	1,563	(248)	(158)	1,503	4,874	(69)
U.S. \$ Millions	(51)	33	83	(254)	(161)	70	267	(74)

## TABLE 13 | COMPARABLE EBITDA

			(%) 3Q:	17 vs.			
3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
(899)	607	1,563	(248)	(158)	1,503	4,874	(69)
(51)	33	83	(254)	(161)	70	267	(74)
1,864	234	26	697	7,162	1,703	(43)	4,106
105	12	2	751	6,542	98	(2)	4,666
965	841	1,589	15	(39)	3,206	4,832	(34)
54	45	85	20	(36)	168	265	(37)
	(899) (51) 1,864 105	(899) 607 (51) 33 1,864 234 105 12	(899) 607 1,563 (51) 33 83 1,864 234 26 105 12 2 965 841 1,589	3Q17     2Q17     3Q16     2Q17       (899)     607     1,563     (248)       (51)     33     83     (254)       1,864     234     26     697       105     12     2     751       965     841     1,589     15	(899)     607     1,563     (248)     (158)       (51)     33     83     (254)     (161)       1,864     234     26     697     7,162       105     12     2     751     6,542       965     841     1,589     15     (39)	3Q17         2Q17         3Q16         2Q17         3Q16         YTD17           (899)         607         1,563         (248)         (158)         1,503           (51)         33         83         (254)         (161)         70           1,864         234         26         697         7,162         1,703           105         12         2         751         6,542         98           965         841         1,589         15         (39)         3,206	3Q17         2Q17         3Q16         2Q17         3Q16         YTD17         YTD16           (899)         607         1,563         (248)         (158)         1,503         4,874           (51)         33         83         (254)         (161)         70         267           1,864         234         26         697         7,162         1,703         (43)           105         12         2         751         6,542         98         (2)           965         841         1,589         15         (39)         3,206         4,832





#### **Plastics & Chemicals**

#### TABLE 14 | REVENUES

				(%) 3Q:	(%) 3Q17 vs.			
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Total Revenues								
Ps. Millions	6,538	6,972	6,573	(6)	(1)	21,180	19,386	9
U.S. \$ Millions	367	375	351	(2)	4	1,119	1,062	5
Domestic Revenues								
Ps. Millions	3,952	4,447	3,990	(11)	(1)	13,024	12,515	4
U.S. \$ Millions	222	239	213	(7)	4	688	686	-
Foreign Revenues								
Ps. Millions	2,587	2,525	2,583	2	-	8,156	6,870	19
U.S. \$ Millions	145	136	138	7	5	430	376	15
Foreign / Total (%)	40	36	39			38	35	

## TABLE 15 | OPERATING INCOME AND EBITDA

				(%) 3Q17 vs.				
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
Operating Income								
Ps. Millions	832	780	1,234	7	(33)	2,894	4,516	(36)
U.S. \$ Millions	47	42	66	11	(29)	151	248	(39)
EBITDA								
Ps. Millions	959	910	1,369	5	(30)	3,316	4,909	(32)
U.S. \$ Millions	54	49	73	10	(26)	173	270	(36)

#### TABLE 16 | COMPARABLE EBITDA

				(%)3Q1	7 vs.			
	3Q17	<b>2Q17</b>	3Q16	2Q17	3Q16	YTD17	YTD16	Ch.%
EBITDA								
Ps. Millions	959	910	1,369	5	(30)	3,316	4,909	(32)
U.S. \$ Millions	54	49	73	10	(26)	173	270	(36)
Adjustments*								
Ps. Millions	(2)	84	(114)	(102)	99	(72)	(253)	71
U.S. \$ Millions	-	5	(6)	(102)	98	(3)	(14)	77
Comparable EBITDA								
Ps. Millions	958	994	1,254	(4)	(24)	3,244	4,656	(30)
U.S. \$ Millions	54	54	67	-	(20)	170	256	(34)





## **Appendix B – Financial Statements**

#### **ALPEK, S.A.B. DE C.V. and Subsidiaries**

#### STATEMENT OF FINANCIAL POSITION

Information in Millions of Mexican Pesos				(%) Sep	17 vs
	Sep 17	Jun 17	Sep 16	Jun 17	Sep 16
ASSETS				-	
CURRENT ASSETS:					
Cash and cash equivalents	7,427	2,675	4,674	178	59
Trade accounts receivable	9,222	10,325	10,820	(11)	(15)
Other accounts and notes receivable	3,938	3,703	3,601	6	9
Inventories	13,204	13,105	13,536	1	(2)
Other current assets	2,145	1,922	2,400	12	(11)
Total current assets	35,936	31,730	35,031	13	3
Investment in associates and others	594	524	855	13	(31)
Property, plant and equipment, net	38,518	37,375	36,511	3	5
Goodwill and intangible assets,net	3,845	10,276	11,497	(63)	(67)
Other non-current assets	4,138	4,181	2,501	(1)	65
Total assets	83,031	84,086	86,395	(1)	(4)
LIABILITIES AND STOCKHOLDER'S EQUITY CURRENT LIABILITIES:					
Debt	6,910	4,218	1,893	64	265
Suppliers	13,493	13,651	12,165	(1)	11
Other current liabilities	3,385	3,323	4,021	2	(16)
Total current liabilities	23,788	21,192	18,079	12	32
NON-CURRENT LIABILITIES:					
Debt (include debt issuance cost)	22,818	17,973	20,503	27	11
Deferred income taxes	4,136	5,022	5,327	(18)	(22)
Other liabilities	1,549	1,609	1,585	(4)	(2)
Employees' benefits	1,118	1,089	1,303	3	(14)
Total liabilities	53,409	46,885	46,797	14	14
STOCKHOLDERS' EQUITY:					
Controlling interest:					(0)
Capital stock	6,048	6,048	6,050	-	(0)
Share premium	9,071	9,071	9,071	-	(0)
Contributed capital	15,119	15,119	15,121	-	(0)
Earned surplus	10,153	17,916	19,843	(43)	(49)
Total controlling interest	25,272	33,035	34,964	(23)	(28)
Non-controlling interest	4,350	4,166	4,634	4	(6)
Total stockholders' equity	29,622	37,201	39,598	(20)	(25)
Total liabilities and stockholders' equity	83,031	84,086	86,395	(1)	(4)



#### **ALPEK, S.A.B. DE C.V. and Subsidiaries**

#### STATEMENT OF INCOME

Information in Millions of Mexican Pesos								
				3Q17 v	rs.(%)			YTD17 vs. (%)
	3Q17	2Q17	3Q16	2Q17	3Q16	YTD17	YTD16	YTD16
Revenues	23,374	24,275	23,131	(4)	1	73,988	66,764	11
Domestic	8,061	9,098	8,408	(11)	(4)	26,791	25,134	7
Export	15,313	15,177	14,723	1	4	47,197	41,630	13
Cost of sales	(21,133)	(22,698)	(20,050)	7	(5)	(66,657)	(56,328)	(18)
Gross profit	2,241	1,577	3,081	42	(27)	7,331	10,436	(30)
Operating expenses and others	(10,618)	(673)	(790)	(1,478)	(1,245)	(12,269)	(2,517)	(387)
Operating income	(8,377)	904	2,291	(1,027)	(466)	(4,938)	7,919	(162)
Financial cost, net	(2,312)	(119)	(526)	(1,847)	(339)	(2,115)	(1,790)	(18)
Share of losses of associates	1	(3)	-	141	536	(4)	(5)	22
Profit (loss) before income tax	(10,688)	782	1,765	(1,467)	(706)	(7,057)	6,124	(215)
Income tax	3,668	(89)	(555)	4,219	761	2,887	(1,776)	263
Consolidated (loss) net income	(7,020)	693	1,210	(1,113)	(680)	(4,170)	4,348	(196)
Profit (loss) attributable to Controlling interest	(7,130)	452	932	(1,680)	(864)	(4,910)	3,081	(259)
Profit attributable to Non-controlling interest	110	241	278	(54)	(60)	740	1,267	(42)